VHL is a critical component of a ubiquitin-conjugating complex that targets the heterodimeric hypoxia-inducible factors (HIF) for degradation under aerobic conditions. these data demonstrate thatin vivooxygenation promotes tolerance of VHL loss in renal epithelia, which may promote the development of renal carcinoma. Mutation of theVHLgene is associated with the hereditary cancer syndrome von Hippel-Lindau disease, which is characterized by central nervous system (CNS) and retinal hemangioblastomas, pheochromocytomas, and clear-cell renal cell carcinomas (CCRCC).VHLis a tumor suppressor that follows the Knudson two-hit model, whereby individuals inherit a mutant allele and then acquire a second, somatically inactivated copy during their lifetimes. Sporadic development of CCRCC is also associated with inactivation ofVHLin a majority of cases. The best-studied role of VHL is in oxygen sensing (16). GKT137831 VHL is a critical component of a ubiquitin-conjugating complex that targets the heterodimeric hypoxia-inducible factors (HIF) for degradation under aerobic conditions. Oxygen-dependent posttranslational modification of the HIF subunits allows association with VHL and subsequent degradation. Under hypoxic conditions, or in the absence of VHL, the HIF transcription complexes are stabilized and activated and lead to the transcription of a diverse set of target genes that are broadly involved in adaptation to low-oxygen conditions. Interestingly, many of these genes have also been linked to protumorigenic functions, including angiogenesis, glycolysis, survival, and metastasis (3). In addition to regulating adaptation to hypoxia, VHL has also been implicated in the maintenance of primary cilia, microtubule stability, and regulation of the extracellular matrix. It is unclear if GKT137831 these functions are specifically linked to tumorigenesis; however, they are likely to contribute to many of the other clinical manifestations of VHL disease (15). In addition, loss of VHL has recently been demonstrated to induce senescence in mouse embryo fibroblasts (MEFs) (41). This observation contributes to an increasingly prevalent theme Rabbit Polyclonal to TEP1 of oncogene activity or tumor suppressor loss in primary cells, leading to senescence to act as a barrier to malignant progression (4,6,22,33). Senescence plays a critical role in tumor suppression. It can result from telomere shortening, oncogene expression/tumor suppressor loss, or adverse culture conditions. Interestingly, senescence is influenced significantly by oxidative stress: oxidizing brokers induce senescence while reducing brokers inhibit senescence. Moreover, senescence can be inhibited by culturing cells GKT137831 in low-oxygen environments (17,25,26). Indeed, under atmospheric oxygen tensions (21% O2, commonly referred to as normoxia), wild-type or oncogene-expressing MEFs display a limited growth potential that culminates in senescence, while under low-oxygen conditions (2 to 3% O2), cells proliferate indefinitely. This increased growth potential is partly due to reduced oxidative stress under low partial O2pressure (pO2) and partly to increased tolerance for such stress (26,38). Given that normal physiological oxygen concentrations range from as high as 14% in the lungs to 1 1 to 2% in parts of the brain, heart, and skin (35), these observations suggest that what induces senescence in atmospheric oxygenin vitromay or may not represent normal cellular responsesin vivo. In the kidney, oxygen ranges from 1.5% in the inner medulla to 7% in the outer cortex (1,18), levels that are often sufficient to alleviate the onset of senescence. As mutation ofVHLhas been found to be one of the earliest lesions in the development of CCRCC (21), we sought to investigate how the loss of VHL would be tolerated under physiological conditions and, in particular, in renal epithelial cells, where VHL mutations occur. Understanding how these cells react to VHL loss is critical to determining the etiology of the disease. == MATERIALS AND METHODS == == Cell culture. == VHLf/fand VHLf/fHIF-2f/fMEFs were harvested as described previously (38). For each experiment, MEFs were thawed and manipulated in 2% O2in a Ruskinn In Vivo2Hypoxia Work Station before being subjected to appropriate pO2in like chambers. Gamma irradiation was carried out with an open-source137Cs irradiator. H2O2treatments were performed with cells at confluence to reduce H2O2toxicity; the cells were plated 24 h later.